Raymond James Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Raymond James Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$265K	Sell	86,214 -28,365	-25%	-$110K	﹤0.01%	4724
2025 Q4	$469K	Sell	114,579 -881	-0.8%	-$4.36K	﹤0.01%	4311
2025 Q3	$563K	Sell	115,460 -2,852	-2%	-$15K	﹤0.01%	4043
2025 Q2	$599K	Sell	118,312 -128,491	-52%	-$631K	﹤0.01%	3900
2025 Q1	$1.31M	Buy	246,803 +156,696	+174%	+$1.14M	﹤0.01%	3295
2024 Q4	$609K	Buy	+90,107	New	+$606K	﹤0.01%	3781

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial's RXRX Position: Q1 2026 in Review

Raymond James Financial reduced its Recursion Pharmaceuticals (RXRX) stake by 25% in Q1 2026, selling an estimated $110K and leaving 86,214 shares worth $265K. The position accounts for ﹤0.01% of the portfolio, ranked #4724.

Raymond James Financial first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.31M in Q1 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Raymond James Financial held 86,214 shares of Recursion Pharmaceuticals worth $265K as of Q1 2026.
Raymond James Financial sold 28,365 Recursion Pharmaceuticals shares in Q1 2026, an estimated $110K.
Recursion Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4724 holding.
Raymond James Financial first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
Raymond James Financial's Recursion Pharmaceuticals position peaked at $1.31M in Q1 2025.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.